A 32-year-old woman is brought to the emergency department by her husband due to agitation… — USMLE Step 3

A 32-year-old woman is brought to the emergency department by her husband due to agitation, confusion, and shivering. She has a history of major depressive disorder, for which she is maintained on citalopram. Three days ago, she visited an urgent care clinic for a severe respiratory infection and was prescribed linezolid. On physical examination, her temperature is $39.4^\circ\text{C}$ ( $102.9^\circ\text{F}$ ), pulse is $122/\text{min}$ , and blood pressure is $165/98 \text{ mm Hg}$ . She is diaphoretic and exhibits ocular clonus and bilateral lower extremity hyperreflexia. Intravenous fluids and benzodiazepines are administered, but her symptoms persist. The physician decides to administer cyproheptadine as a targeted antidote. Which of the following best describes the expected pharmacodynamic effect of this antidote on the dose-response curve of the involved endogenous neurotransmitter?

A
Decrease in $E_{max}$ with no change in apparent $EC_{50}$
B
Decrease in both $E_{max}$ and apparent $EC_{50}$
C
Apparent decrease in $EC_{50}$ with no change in $E_{max}$
Apparent increase in $EC_{50}$ with no change in $E_{max}$ Answer
E
Increase in both $E_{max}$ and apparent $EC_{50}$

Answer

Cyproheptadine acts as a competitive antagonist, which causes an apparent increase in the

EC_{50}

of serotonin without changing its maximal efficacy (

E_{max}

The patient presents with classic signs of Serotonin Syndrome (hyperthermia, autonomic instability, hyperreflexia, ocular clonus) caused by the interaction between citalopram (an SSRI) and linezolid (an antibiotic with weak MAOI properties). When initial supportive care and benzodiazepines are insufficient, cyproheptadine is the antidote of choice. Cyproheptadine is a first-generation histamine antagonist with non-selective, competitive serotonin receptor antagonist properties (particularly at

5-HT_{2A}

receptors). In pharmacodynamics, a competitive antagonist reversibly binds to the same receptor site as the endogenous agonist. This means higher concentrations of the agonist (serotonin) are required to achieve the same physiological response, leading to a shift of the dose-response curve to the right and an apparent increase in the

EC_{50}

. However, because the binding is competitive and reversible, adding sufficiently high amounts of the agonist can overcome the antagonism, so the maximal efficacy (

E_{max}

) remains unchanged.

Step-by-Step Solution

Identify the clinical syndrome based on the patient's presentation and medication history.

The patient has Serotonin Syndrome due to the combination of an SSRI (citalopram) and an antibiotic with MAOI properties (linezolid).

Recognizing the underlying toxidrome is required to determine the appropriate targeted therapy and understand its mechanism.

Determine the mechanism of action of the administered antidote (cyproheptadine).

Cyproheptadine is a non-selective, competitive antagonist of serotonin (particularly at 5-HT2A receptors).

The question specifically asks about the pharmacodynamic classification of this antidote.

Apply pharmacodynamic principles to predict the effect of a competitive antagonist on the endogenous agonist's dose-response curve.

Competitive antagonists compete for the same receptor site as the agonist, increasing the concentration of agonist needed to achieve 50% of the maximum effect (increased apparent

EC_{50}

). However, the maximal effect (

E_{max}

) can still be reached if enough agonist is present.

This directly answers how the dose-response curve shifts in the presence of the antidote.

Key Concept

Competitive antagonists shift the agonist dose-response curve to the right (increase in apparent

EC_{50}

) without altering the maximal response (

E_{max}

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic